论文部分内容阅读
目的:探讨雌激素受体(ER)和人表皮生长因子受体(HER-2)在人乳腺浸润性导管癌肿瘤病灶与腋窝转移淋巴结中表达的关系。方法:检测80例乳腺癌肿瘤病灶和转移淋巴结中ER(免疫组化法)和HER-2(荧光原位杂交法)的表达情况,并分析两者相关性与一致性。结果:80例患者中,乳腺癌肿瘤病灶ER阳性34例(42.50%),HER-2阳性26例(32.50%);腋窝淋巴结转移灶ER阳性37例(46.25%),HER-2阳性27例(33.75%),两者在肿瘤病灶与腋窝淋巴结的阳性率差异均无统计学意义(P=0.750,P=1.000)。肿瘤病灶与腋窝转移淋巴结ER均阳性32例,HER-2均阳性22例,肿瘤病灶与腋窝转移淋巴结两种受体表达情况总符合率为83.75%,两者在原发灶与腋窝淋巴结转移灶的表达具有较好的相关性和一致性(r=0.825,0.746;κ=0.823,0.764)。结论:人乳腺浸润性导管癌肿瘤病灶与腋窝转移淋巴结中ER和HER-2表达具有较好的相关性与一致性。
Objective: To investigate the relationship between the expression of estrogen receptor (ER) and human epidermal growth factor receptor (HER-2) in the metastatic lymph node of human breast invasive ductal carcinoma. Methods: The expression of ER (immunohistochemistry) and HER-2 (fluorescence in situ hybridization) in 80 cases of breast cancer and metastatic lymph nodes were detected, and their correlation and consistency were analyzed. RESULTS: Among the 80 patients, the positive rate of ER was 34 (42.50%) in breast cancer and 26 (32.50%) in HER-2. The positive rate of ER was 37 (46.25%) in HER- (33.75%). There was no significant difference in the positive rates of tumor lesions and axillary lymph nodes (P = 0.750, P = 1.000). Tumor lesions and axillary lymph node metastasis ER were positive in 32 cases, HER-2 were positive in 22 cases, tumor lesions and axillary lymph node metastasis of the two receptors were consistent with the rate of 83.75%, both in the primary tumor and axillary lymph node metastases (R = 0.825,0.746; κ = 0.823,0.764). Conclusion: There is a good correlation and consistency between ER and HER-2 expression in invasive ductal carcinoma of human breast and axillary lymph node metastasis.